Estrogen receptor beta expression correlates with proliferation in desmoid tumorsShow others and affiliations
2019 (English)In: Journal of Surgical Oncology, ISSN 0022-4790, E-ISSN 1096-9098, Vol. 119, no 7, p. 873-879Article in journal (Refereed) Published
Abstract [en]
BACKGROUND AND OBJECTIVES: Estrogen receptor signaling and cyclin D1 have a major role in tumor cell proliferation in breast cancer. Desmoid tumors are rare neoplasms that may respond to endocrine treatment. The present study aimed to investigate the expression levels and the clinical relevance of estrogen receptor beta (ERβ) and cyclin D1 in desmoid tumors.
METHODS: This study consists of 83 patients with a surgically treated desmoid tumor. ERβ and cyclin D1 expression was examined by immunohistochemistry in tissue microarrays. Cyclin A and Ki67 were studied in our previous work.
RESULTS: = 0.34, P = 0.004). ERβ immunoexpression showed a trend towards predictive impact for recurrence as a continuous variable. Further explorative analysis indicated that very high ERβ expression was related to high risk of relapse (hazard ratio [HR] 2.6; P = 0.02). Median cyclin D1 expression was 15.6%. High cyclin D1 expression was associated with high Ki67 and cyclin A expression. Cyclin D1 was not associated with time to recurrence.
CONCLUSIONS: ERβ and cyclin D1 immunopositivity correlated with high proliferation in desmoid tumors. High ERβ expression might be predictive for postoperative recurrence.
Place, publisher, year, edition, pages
Wiley-Interscience Publishers , 2019. Vol. 119, no 7, p. 873-879
Keywords [en]
Aggressive fibromatosis, biomarkers, cyclins, immunohistochemistry, steroid receptors
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-72476DOI: 10.1002/jso.25407ISI: 000476938900008PubMedID: 30742303Scopus ID: 2-s2.0-85061430442OAI: oai:DiVA.org:oru-72476DiVA, id: diva2:1288894
Note
Funding Agencies:
Sigrid Juseliuksen Saatio
Finska Läkaresällskapet
Medicinska Understödsforeningen Liv och Hälsa
Helsinki University Hospital Research funds
2019-02-142019-02-142019-11-08Bibliographically approved